Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Trial Details

NCT ID
NCT06824818
Phase
NA
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • LHRH Agonist Therapy Discontinuation
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Prostate cancer with \>3 years of LHRH agonist therapy.
  • Age ≥70 years.
  • ECOG performance status ≤2
  • Baseline testosterone of \< 20 ng/ml

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →